कंपनी का अवलोकन
DENTSPLY SIRONA Inc. operates as a global manufacturer and marketer specializing in dental equipment supported by cloud-enabled solutions, alongside a diverse range of dental products and healthcare consumables for urology and enterology. The company functions within the healthcare sector, specifically targeting the medical instruments and supplies industry, which serves the critical infrastructure of patient care and diagnostic procedures. Its operational scale is substantial, evidenced by a market capitalization of $2.39 billion, annual revenue reaching $3.68 billion, and a workforce comprising 14,000 employees worldwide. These financial figures indicate that the entity holds a significant position in the medical device landscape, with revenue generation sufficient to support a large global employee base while maintaining a valuation that reflects its established presence in specialized healthcare markets.
वित्तीय स्वास्थ्य
The financial statements reveal a revenue of $3.68 billion for the trailing twelve months, yet this is contrasted by a net income of -$598,000,000, highlighting a substantial gap between top-line growth and profitability. This disparity between revenue and net income indicates a challenging cost structure where operating expenses or one-time charges significantly erode earnings, resulting in a negative profit environment despite robust sales. However, the company maintains an EBITDA of $597.00 million, suggesting that core operational cash generation before interest and taxes remains positive even as net income turns negative. Free cash flow stands at $106.38 million, which provides the company with essential financial flexibility to fund capital expenditures, repay debt obligations, or pursue strategic acquisitions without immediate reliance on external financing. The margin profile shows a gross margin of 50.0%, reflecting high pricing power in manufacturing and supply, while the operating margin sits at a narrow 1.8% and the profit margin is negative at -16.2%, signaling that fixed cost structures are currently pressuring bottom-line returns. Balance sheet analysis shows cash reserves of $354.00 million against total debt of $2.48 billion, creating a leverage situation where liabilities exceed liquid assets by a wide margin. The debt-to-equity ratio is reported at 185.00, indicating a highly leveraged capital structure that amplifies financial risk relative to equity holders. Liquidity is assessed via a current ratio of 1.51, which suggests the company holds sufficient current assets to cover short-term liabilities, though not comfortably given the high debt load. Return on equity is -36.4% and return on assets is 2.7%, revealing that management effectiveness in generating returns for shareholders is currently impaired, while asset utilization remains marginally positive but insufficient to offset equity dilution pressures.
मूल्यांकन आकलन
Valuation metrics present a complex picture with a forward P/E of 7.71, while the trailing P/E is marked as N/A due to the lack of positive earnings over the trailing twelve months. The absence of a trailing P/E compared to the existence of a forward P/E implies that the market is pricing in a significant expected earnings turnaround rather than current profitability performance. The price-to-book ratio is 1.79, indicating that the stock trades at a modest premium above its book value, which may reflect intangible assets or future growth potential despite current losses. Alternative valuation multiples show a price-to-sales ratio of 0.65 and an EV/EBITDA of 7.57, suggesting the company is valued at a significant discount relative to its sales volume and operational cash flow generation. Price action over the last year ranges between a 52-week high of $17.18 and a 52-week low of $9.85, with the current trading price situated within this historical band but closer to the lower end given the negative net income context. The beta value is 1.00, meaning the stock's price volatility mirrors the broader market movements exactly, offering no inherent hedge or amplification relative to systemic market risks. These metrics collectively suggest a valuation that relies heavily on future operational improvements rather than current earnings power or asset backing.
Growth & Income
Revenue growth year-over-year stands at 6.2%, demonstrating consistent top-line expansion in the medical devices sector, whereas earnings growth is N/A due to the negative net income position. The divergence between positive revenue growth and absent earnings growth implies that cost pressures or structural losses are outpacing top-line gains, preventing the translation of sales increases into shareholder value. The company maintains a dividend yield of 5.0% with a payout ratio of 28.8%, which appears mathematically sustainable based on current cash flow metrics despite the negative net income figure. This high payout ratio relative to negative earnings suggests the dividend is being funded primarily from free cash flow and cash reserves rather than distributable net income, a strategy that carries inherent risk if operating cash flows decline. The overall growth and income profile is characterized by steady sales expansion supported by a substantial cash position and a high dividend yield, though the negative net income and high leverage create significant headwinds for sustainable earnings growth in the near term.